Cargando…
Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report
Acute myeloid leukemia (AML) with FUS‐ERG has a poor prognosis regardless of allo‐hematopoietic stem cell transplantation (HSCT). Maintenance therapy such as azacitidine after allo‐HSCT for AML with FUS‐ERG may be clinically meaningful.
Autores principales: | Keino, Dai, Mori, Takashi, Morimoto, Mizuho, Kondo, Kensuke, Mori, Tetsuya, Kinoshita, Akitoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878075/ https://www.ncbi.nlm.nih.gov/pubmed/31788268 http://dx.doi.org/10.1002/ccr3.2461 |
Ejemplares similares
-
A case of pediatric ALL with t(16;21)(p11.2;q22) and FUS-ERG rearrangement
por: Coccé, Mariela C., et al.
Publicado: (2015) -
Acute basophilic leukemia associated with the t(16;21)(p11;q22)/FUS‐ERG fusion gene
por: Toda, Yusuke, et al.
Publicado: (2017) -
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
por: Asai-Nishishita, Ai, et al.
Publicado: (2023) -
The oncofusion protein FUS–ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia
por: Sotoca, A M, et al.
Publicado: (2016) -
Relapse of Acute Myeloid Leukemia with t(16;21)(p11;q22) Mimicking Autoimmune Pancreatitis after Second Allogeneic Bone Marrow Transplantation
por: Kamada, Yuhei, et al.
Publicado: (2011)